Yang et al (2014) Retrospective CS Patients with stage Ia or Ib peripheral NSCLC, who were Intervention: CT-guided 1. Overall survival and local control: Kaplan-Meier test (for medically inoperable or declined surgery MTA all survival outcomes) China Level IV N = 47 (47) Local anaesthesia 2. Local progression: defined as the contrast enhancement Risk of bias: High by CT scans in the site of ablation Maximum tumour sixe > 35 mm in 24, ≤ 35 mm in 23 Duration: preset ablation Hospital setting time was 6–8 minutes 3. Therapeutic outcome of MTA: measured using the Male/Female ratio: 29:18 30 (7–70) months modified RECIST criteria Comparator: N/A Mean age 69.4 (range 56–82) years 4. Adverse events: reported according to terminology Comorbidities (n, %) were: pulmonary disease (19, 40.4%), outlined by Ahmed et al (2014) and Goldberg et al (2005) cardiovascular disease (39, 83%), diabetes mellitus (16, 34%), renal insufficiency (2, 4.3%), refusal of surgery (1, 2.1%) POPULATION 2 Qi et al (2015) Retrospective CS Patients with lung metastases (from nasopharyngeal Intervention: CT-guided 1. Treatment response: ssessed by CTd carcinoma) whose primary lesions were in complete MTA China Level IV 2. Local control: measured by number of new metastases remission Anaesthesia: NR inside the lung Risk of bias: High N = 17 (29) Duration: range of 5–10 Hospital setting Tumour size: range: 8–42 mm minutes Mean: 14 (3–24) months Male/Female ratio: 15:2 Comparator: N/A Mean age 45.7 (range 28–65) years Prior treatments included (n, %): radical radiotherapy (all patients), neoadjuvant/adjuvant chemotherapy (14, (82%), failed systemic chemotherapy (10, 58.8%), recurrence after surgery (2, 11.8%)
Yang et al (2014) China Retrospective CS Level IV Risk of bias: High Hospital setting 30 (7–70) months Patients with stage Ia or Ib peripheral NSCLC, who were medically inoperable or declined surgery N = 47 (47) Maximum tumour sixe > 35 mm in 24, ≤ 35 mm in 23 Male/Female ratio: 29:18 Mean age 69.4 (range 56–82) years Comorbidities (n, %) were: pulmonary disease (19, 40.4%), cardiovascular disease (39, 83%), diabetes mellitus (16, 34%), renal insufficiency (2, 4.3%), refusal of surgery (1, 2.1%) Intervention: CT-guided MTA Local anaesthesia Duration: preset ablation time was 6–8 minutes Comparator: N/A 1. Overall survival and local control: Kaplan-Meier test (for all survival outcomes) 2. Local progression: defined as the contrast enhancement by CT scans in the site of ablation 3. Therapeutic outcome of MTA: measured using the modified RECIST criteria 4. Adverse events: reported according to terminology outlined by Ahmed et al (2014) and Goldberg et al (2005) POPULATION 2 Qi et al (2015) China Retrospective CS Level IV Risk of bias: High Hospital setting Mean: 14 (3–24) months Patients with lung metastases (from nasopharyngeal carcinoma) whose primary lesions were in complete remission N = 17 (29) Tumour size: range: 8–42 mm Male/Female ratio: 15:2 Mean age 45.7 (range 28–65) years Prior treatments included (n, %): radical radiotherapy (all patients), neoadjuvant/adjuvant chemotherapy (14, (82%), failed systemic chemotherapy (10, 58.8%), recurrence after surgery (2, 11.8%) Intervention: CT-guided MTA Anaesthesia: NR Duration: range of 5–10 minutes Comparator: N/A 1. Treatment response: ssessed by CTd 2. Local control: measured by number of new metastases inside the lung
1403%20-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx